COLORADO SPRINGS, Colo.,
Feb. 2, 2015 /PRNewswire/
-- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, today announced several updates and significant
progress on product commercialization and key developments
domestically and internationally from the Americas to Africa to Hong
Kong, a key door to Asia.
Highlights
"Overall, the medical cannabis industry is
booming and it doesn't show any signs of slowing down," said
Raymond C. Dabney, the company's
Director, President & CEO and Co-Founder. "In the next two
years, a number of states are expected to consider the
legalization of both recreational and medical cannabis. While
recreational use is not a part of our business model, we do believe
its public and legislative support is one of the key litmus tests
for acceptance of medical cannabis." Please see sector growth
charts from January 29, 2015 in the
Huffington Post.
Dabney said Cannabis Science made great strides in 2014,
establishing partnerships and joint ventures with partners around
the world. He added that the company is ready to move to the
next level in 2015 in terms of expansion of public awareness,
commercialization of products, and expansion of capacity to address
serious health issues in the U.S. and internationally. This
includes the Company's African initiative. Also, not
previously announced, Dabney and key team members recently returned
from Hong Kong, where promising
relationships were formed for the Company's many initiatives in
Asia.
"One of the final steps in taking operations in 2015 to the next
level is putting in place a strong media program," said Dabney. "We
are proud to announce we have just retained top media experts to
drive media interest in the Company and also in the
Foundation." Forward looking media coverage will assist the
Company's team in sharing and expanding on its core mission: to
develop, produce, and commercialize truly novel therapeutic
approaches for the treatment of critical ailments from cancer and
infections to age-related illnesses and neurobehavioral disorders
for patients in need. "And Cannabis Science's team is
stronger that ever, enhanced by its collaboration with leading
experts in drug development, medicinal characterization and
clinical research," noted Dabney. Please see Cannabis Science's
expanding Scientific Advisory Board.
New retail locations in two European countries as well as
California
Cannabis Science
is making final preparations to bring its products to market and
has finalized preliminary retail locations in Spain and the
Netherlands, and sites in California. With these
successes, the Company expects an increase in demand in these
jurisdictions, others that the Company has announced, and more
being actively targeted.
These cannabis and cannabinoid-based products are currently
ready for pre-clinical studies, self-medicating patient usage, and
marketing release, sales and distribution. The Company is also
developing processes to efficiently produce, distribute and market
products along with the proper procurement of opt-in, informed
consent data collection regarding patient outcomes. This will
establish Cannabis Science with a vertically integrated product
pipeline to accommodate varied established and emerging
international markets.
The Cannabis Science product launch will begin in the Netherlands and Spain within the next week, and in
California the following week.
A strong new partnership in Michigan
In the United States, Cannabis Science is leading
the market in Michigan through its
subsidiary, Michigan Green Technologies, LLC (MGT), which is
recognized as the foremost resource for Michigan legislative initiatives and
management consulting in respect of cannabinoid-based drug
development, nutraceuticals, cosmeceuticals, and food
supplements. Following a slight administrative delay, MGT is
now poised to lead Michigan into a
much larger and more successful version of the experience witnessed
in Colorado.
Success in California
Cannabis Science also
successfully renegotiated its agreement with Apothecary Genetics
Investments LLC to purchase and license two northern California production farms with a combined
total of 51 acres. The purchase includes all related equipment for
cannabis cultivation and production for the state's substantial
medical cannabis market. The Company is in the final stages
of its preparations to launch new products throughout the
California market, including
extracts, oils, tinctures, tablets, and creams.
"The overall goal of Cannabis Science in the United States is to offer products as soon
as it is legally possible in each state," said Dabney. "We know the
medical need is there, and that means the market is poised and
waiting for Cannabis Science in California and beyond."
Research around the world
In Spain and the
Netherlands, Cannabis Science is working closely with the
Mediwiet Foundation to conduct an observational study with patients
who are self-treating with medicinal cannabis. Cannabis Science
also began pre-clinical studies on its CBN patent in Italy and is collaborating with Unistraw in an
exciting effort to produce proprietary formulations delivering a
wide array of unique cannabis extracts and pure cannabinoid-based
products.
The Company is also negotiating with groups in South American
countries, such as Uruguay and
Colombia, and is exploring similar
opportunities in Mexico. All of
these countries are part of the Company's fundamental plan to
create a network for efficient licensing and distribution for
medical cannabis formulations and products. The Company
intends to add East Asia and
Australasia to this network and will make further announcements as
developments warrant.
Continued development of an African initiative
Through
foundations like the Constituency for Africa, Cannabis Science is also developing
political strategies for low-cost cannabis-based therapeutics to
address the lack of access to pain medications and other needed
treatments in Africa. This initiative has both philanthropic
and commercial elements.
Cannabis Science had recently launched the Patient Access Centre
and the Cannabis Science Research Foundation, among other things,
to bring the public together to increase public awareness and
generate humanitarian contributions to help patients in
need.
Join the PAC (Patient Access Centre)
See the Cannabis Science Research Foundation Website
About Cannabis Science, Inc.
Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The Company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science, Inc
Raymond
C. Dabney
Director, President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq.
Director, COO & General Counsel
www.cannabisscience.com
Tel: 1.888.889.0888
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-provides-guidance-on-the-companys-new-year-and-products-developments-and-initiatives-in-action-for-2015-300029053.html
SOURCE Cannabis Science, Inc.